Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

Université Laval

$27,000.00

Cardiac Damage Staging in Patients with Bicuspid Aortic Valve and Aortic Stenosis

FY 2025-26

Summary
The bicuspid aortic valve (BAV) is the most common congenital heart defect present from birth, affecting 1–2% of people. Normally, the aortic valve has three leaflets (tricuspid) that control blood, but in people with BAV, it has only two. This can cause the valve to work improperly, most often leading to aortic stenosis (AS, narrowing of the valve) and/or aortic regurgitation (AR, leaking of the valve). AS is the most common valve problem in developed countries. It results in increased thickening and stiffness of the valve leaflets, blocking blood flow from the left ventricle to the aorta. BAV patients are also presenting with abnormal aorta. AR occurs when blood leaks back from the aorta into the left ventricle due to improper valve closure. Currently, no medication can prevent or slow the progression of these diseases. The only effective treatment is aortic valve replacement or repair, either through open-heart surgery or less invasive catheter procedure. While these treatments can save lives, they still carry risks and do not always improve quality of life. To guide treatment, doctors use a system that describes how much the heart is affected by a valve disease. This system tracks damage through the heart chambers and helps predict outcomes. However, because BAV patients develop valve problems earlier and differently, the existing system does not reflect their situation. Developing a new system specifically for BAV patients would allow to better plan care of the patients, monitor disease progression, and improve long-term outcomes.
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
573105
Name
Constantin Laurence
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Cardiac Damage Staging in Patients with Bicuspid Aortic Valve and Aortic Stenosis
Programtype2
Studentship Programs
Orgnameinp2
Université Laval
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Aortic Regurgitation; Aortic Stenosis; Aortic Valve; Artopathy; Bicuspid Aortic Valve; Cardiac Damage; Cardiology; Congenital Abnormality; Imaging; Staging
Abstract
The bicuspid aortic valve (BAV) is the most common congenital heart defect present from birth, affecting 1–2% of people. Normally, the aortic valve has three leaflets (tricuspid) that control blood, but in people with BAV, it has only two. This can cause the valve to work improperly, most often leading to aortic stenosis (AS, narrowing of the valve) and/or aortic regurgitation (AR, leaking of the valve). AS is the most common valve problem in developed countries. It results in increased thickening and stiffness of the valve leaflets, blocking blood flow from the left ventricle to the aorta. BAV patients are also presenting with abnormal aorta. AR occurs when blood leaks back from the aorta into the left ventricle due to improper valve closure. Currently, no medication can prevent or slow the progression of these diseases. The only effective treatment is aortic valve replacement or repair, either through open-heart surgery or less invasive catheter procedure. While these treatments can save lives, they still carry risks and do not always improve quality of life. To guide treatment, doctors use a system that describes how much the heart is affected by a valve disease. This system tracks damage through the heart chambers and helps predict outcomes. However, because BAV patients develop valve problems earlier and differently, the existing system does not reflect their situation. Developing a new system specifically for BAV patients would allow to better plan care of the patients, monitor disease progression, and improve long-term outcomes.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Constantin, Laurence
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~